Angelini Ventures
Angelini Ventures is the Rome-based corporate venture capital arm of Angelini Industries, the Italian family-owned pharma and consumer group, established in 2022 with a EUR 300 million commitment to build and back early-stage biotech, life sciences and digital health companies across Europe, North America, Israel and Asia. It invests directly and through vehicles such as the Angelini Lumira Biosciences Fund (a North American partnership with Lumira Ventures) and the biotech venture studios Argobio in Paris and Extend in Milan, and in December 2025 signed a EUR 150 million co-investment agreement with the European Investment Bank to scale European healthcare startups. It is distinct from the group operating company Angelini Pharma.
Key facts
Recent exits
Coverage notes
1 fund tracked, 26 portfolio companies (25 active · 1 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
26 companiesFunds & portfolio
Every fund Angelini Ventures has raised, with its portfolio companies. Hand-checked from public filings.
Angelini VenturesLife Sciences VCActive2022 · 4yr€300M25 active · 1 realized
Unrealized
25 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  France | 2025 | |
| Biotech |  US | 2022 | |
| Biotech | France | 2021 | |
| MedTech | US | 2023 | |
| MedTech | US | 2023 | |
| MedTech |  UK | 2023 | |
| Biotech | Canada | 2021 | |
| Biotech | US | 2023 | |
| Biotech | Canada | 2022 | |
| Biotech | France | 2025 | |
| Biotech |  Italy | 2022 | |
| Biotech |  Denmark | 2023 | |
| Biotech | US | 2021 | |
| HealthTech | US | 2026 | |
| MedTech | UK | 2026 | |
| Biotech |  Netherlands | 2025 | |
| Biotech | Denmark | 2024 | |
| MedTech |  Belgium | 2025 | |
| Biotech |  Switzerland | 2024 | |
| Biotech | Switzerland | 2025 | |
| Biotech | Singapore | 2025 | |
| Biotech | US | 2021 | |
| HealthTech | Italy | 2022 | |
| Biotech | US | 2025 | |
| HealthTech |  Germany | 2025 |
France· Entry 2025US· Entry 2022France· Entry 2021US· Entry 2023US· Entry 2023UK· Entry 2023US· Entry 2023France· Entry 2025Italy· Entry 2022Denmark· Entry 2023US· Entry 2021US· Entry 2026UK· Entry 2026Netherlands· Entry 2025Denmark· Entry 2024Belgium· Entry 2025Switzerland· Entry 2024Switzerland· Entry 2025US· Entry 2021Italy· Entry 2022US· Entry 2025Germany· Entry 2025Realized
1 exit| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| MedTech | US | 2023 | 2026 | Trade Sale | – |
Saved GPs appear in your watchlist, one click from your workspace.
Similar firms
Other private equity firms tracked on GP Intel.
Italy·€270M
Italy·€250M
Italy·€250M
Italy·€363M
Italy·€212M
Italy·€180M
Italy·€454M
Italy·€125M
Italy·€120M
Italy·€110M
Italy·€500MItaly·€100MGet the full picture on Angelini Ventures.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in